Ieuan Jones
Novartis (Switzerland)(CH)
Publications by Year
Research Areas
Asthma and respiratory diseases, Allergic Rhinitis and Sensitization, Respiratory and Cough-Related Research, Inhalation and Respiratory Drug Delivery, Chronic Obstructive Pulmonary Disease (COPD) Research
Most-Cited Works
- → Intravenous anti–IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis(2014)304 cited
- → Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity(1995)287 cited
- → Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high‐affinity anti‐IgE antibody, in atopic subjects(2014)240 cited
- → Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial(2013)147 cited
- → Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti–IL-4: A randomized controlled trial(2015)62 cited
- → Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma(2023)62 cited
- → <p>Efficacy and Safety of the CFTR Potentiator Icenticaftor (QBW251) in COPD: Results from a Phase 2 Randomized Trial</p>(2020)59 cited
- → Implementation of a Bayesian adaptive design in a proof of concept study(2006)53 cited
- → Bayesian Design of Proof-of-Concept Trials(2014)51 cited
- → Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251)(2020)24 cited